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ABSTRACT
P u r p o s e : S u b je c t iv e  a n d  o b je c t iv e  r e s u lt s  w e re  a s s e s s e d  a f te r  la s e r  p ro s ta te c to m y  w it h  th e  
U r o la s e *  f ib e r  a t  5 d if f e r e n t  c e n te rs  in  T h e  N e th e r la n d s .
M a t e r ia ls  a n d  M e th o d s : P a t ie n t s  w e r e  e v a lu a te d  w it h  th e  in t e r n a t io n a l p r o s ta t ic  s y m p to m  
s c o re  q u e s t io n n a ir e , u r o f lo w m e t r y  a n d  p o s t- vo id  r e s id u a l v o lu m e  m e a s u re m e n ts . U ro d y n a m ic  
in v e s t ig a t io n s  w it h  p re s s u re - f lo w  a n a ly s is  w e re  p e rfo rm e d  a t  2  c e n te rs .
R e s u lt s :  D a t a  fo r  2 3 3  p a t ie n t s  w e re  e v a lu a te d . O v e r a ll s ig n if ic a n t  im p ro v e m e n t in  m e a n  
in t e r n a t io n a l p r o s ta t ic  s y m p to m  sc o re , m a x im u m  flo w , p o s t- vo id  r e s id u a l a n d  u ro d y n a m ic  p a ­
r a m e te r s  w a s  n o te d . D if fe r e n c e s  in  o u tc o m e  a m o n g  th e  c e n te rs  m a y  b e  d u e  to  v a r ia t io n  o f 
te c h n iq u e  o r  d if f e r e n t  s e le c t io n  c r it e r ia .  P o s to p e r a t iv e  m o rb id ity  w a s  s ig n if ic a n t , w it h  ir r i t a t iv e  
v o id in g  c o m p la in ts  fo r  4  to  6  w e e k s  in  u p  to  5 0 %  o f  a l l p a t ie n ts  a n d  u r in a r y  t r a c t  in fe c t io n s  in  
21 . 1% ,
C o n c lu s io n s : L a s e r  p ro s ta te c to m y  r e s u lt s  in  s u b je c t iv e  a n d  o b je c t iv e  im p ro v e m e n t, w h ic h  is  
o p e ra to r  in d e p e n d e n t . D e s p ite  th e  o b s e r v a t io n  t h a t  p e r io p e ra t iv e  ( in t r a o p e r a t iv e  a n d  im m e d ia te  
p o s to p e r a t iv e )  m o r b id it y  s e e m s  le s s  s e v e re  c o m p a re d  to  t r a n s u r e t h r a l re s e c t io n  o f th e  p ro s ta te , 
th e r e  is  a  s h if t  t o w a r d  g r e a t e r  p o s to p e ra t iv e  m o rb id ity .
K e y  W o r d s : lasers, prostatectom y, prostatic hypertrophy, urodynam ics
Benign prostatic hyperplasia (B P H ) has a high prevalence 
in  men older than 50 years, the m ajority of whom w ill even­
tually have voiding complaints and require treatment.1 
Transurethral electroresection of the prostate has proved to 
be safe and effective, w ith  excellent long-term results. The 
m ortality rate has decreased from 2.5 to 0.2% but morbidity 
has remained unchanged at 18% w ith in  the first 90 days 
after transurethral resection of the prostate2 and probably is 
even greater after 1 year. This m orbidity rate is a main 
reason to seek less invasive treatm ent modalities, causing 
m inim al m orbidity while m aintaining the same results as 
after transurethral resection of the prostate. Despite the 
challenge of numerous alternative operative and nonopera­
tive therapies,3“7 transurethral resection of the prostate and 
open prostatectomy rem ain the gold standards in  the treat­
ment of B PH , m ainly because the clin ical outcome of alter­
native treatments is significantly less successful. A  promis­
ing, recently introduced alternative treatm ent of B P H  seems 
to be laser energy.
In  1985 Shanberg et al used laser energy to treat BPH ,8 
W ith  an end firing, bare fiber used in  contact w ith tissue, 
causing vaporization, the main purpose was to make pros­
tatic incisions. The incidence of postoperative bleeding was 
significant and, furthermore, it was difficult to aim the laser 
beam at the prostatic lobes. Development of a side firing 
device solved this problem, and after canine feasibility stud­
ies Costello et al performed laser prostatectomies in  men 
w ith a free beam side firing  system under cystoscopic guid­
ance.9 McCullough et al performed transurethral ultrasound 
guided laser ablation of the prostate (T U L IP ).10 Also, the 
understanding and acceptance of coagulation as a deeper 
tissue penetrating effect compared to vaporization allowed 
for development of an efficient and effective neodymium:YAG 
laser procedure. Since then, several different free beam, side
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firing laser fibers for contact or noncontact use have been 
developed. Besides side firing fiber techniques, other laser 
applications for interstitial or contact vaporization were de­
veloped and are currently under clinical investigation.
A  widely used and investigated laser fiber is the side firing, 
noncontact Urolase fiber. Most studies using this device to 
treat B P H  showed good subjective and objective results.11“14 
However, the extent of improvement differed in many stud­
ies. We investigated the clinical outcome of laser prostatec­
tomy at different centers in the Netherlands. Is laser pros­
tatectomy operator dependent or can variation in  clinical 
outcome be explained by differences in treatment protocol? 
The only way to demonstrate effectiveness of treatment for 
B PH  is to perform urodynamic investigations before and 
after the procedure. There are few studies of urodynamics 
used to demonstrate effectiveness of laser prostatecto­
my.15“18 We performed urodynamic investigations before and 
6 months after treatment of B PH  with the Urolase side firing 
laser at 2 university centers.
M A T ER IA L AND M ETH O DS
Each participating center included at least 10 patients who 
underwent laser prostatectomy with the Urolase fiber. 
Guidelines for selecting patients for laser prostatectomy 
were age greater than 50 years, duration of symptoms longer 
than 3 months, international prostatic symptom score (I- 
PSS) greater than 12, maximum flow less than 15 ml. per 
second and voided volume greater than 100 ml. Despite these 
criteria, 2 centers treated all patients who normally would 
undergo transurethral resection of the prostate. Therefore, 
from these 2 centers 3 patients with a maximum flow of more 
than 15 ml. per second and 7 with an I-PSS of less than 12 
underwent laser prostatectomy. Patients in urinary reten­
tion, or those with urethral stricture, previous prostatic sur­
gery, diabetes mellitus or neurogenic bladder dysfunction 
were excluded from the study. A ll patients were evaluated
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with I-PSS and sexual function questionnaires, maximum 
flow and post-void residual volume preoperatively, and at 3, 
6 and 12 months postoperatively. Physical examination (in ­
cluding digital rectal examination), transrectal ultrasound 
with measurement of prostate volume, laboratory investiga­
tions (including prostate specific antigen) and urine cultures 
were performed preoperatively. Urine was also cultured 2 
and 4 weeks after removal of the catheter or in cases suspi­
cious for urinary tract infection. U rine was considered in ­
fected when culture yielded more than 105/ml. of a pure 
organism. A ll patients w ith an abnormal digital rectal exam­
ination and/or elevated prostate specific antigen underwent 
transrectal ultrasound guided biopsies of the prostate. Pa ­
tients w ith histologically proved adenocarcinoma were ex­
cluded from the study.
Urodynamic investigations were performed at 2 centers 
preoperatively and 6 months postoperatively w ith an 8F 
transurethral lumen catheter and an intravesical microtip 
pressure sensor. Pressure and flow data were recorded digi­
tally w ith commercially available equipment and urody­
namic analysis software. To quantify grade of obstruction 
different parameters were used, including detrusor pressure 
at maximal flow (grading according to the Abrams-Griffith 
nomogram),19 intersection of quadratic urethral resistance 
relation w ith pressure axis of pressure flow (urethral resis­
tance relation) and linear passive urethral resistance rela­
tion (an approximation of the resistance relation by a 
straight line through m inim al detrusor pressure and detru­
sor pressure at maximum flow, w ith grading according to the 
Schäfer nomogram).20
A ll patients were treated via  the 4-quadrant technique at 
the 2, 5, 7 and 10 o’clock positions w ith a power setting of 40 
W. for 90 seconds, which has been described previously.14 An 
enlarged middle lobe was treated w ith 1 or 2 laser applica­
tions. Each patient was treated w ith a new fiber. However, at 
all centers slight modifications were introduced, and addi­
tional prostatic tissue was treated after the 4-quadrant ap­
plications. Before laser therapy was begun cystourethroscopy 
was performed and a Ch. 16 suprapubic catheter was intro­
duced. The suprapubic catheter was removed when the pa­
tient could void spontaneously w ith a residual of less than 50 
ml. Patients were discharged from the hospital 1 day post­
operatively.
The Kruskal-W allis test was used for statistical compari­
son of results among the different centers. The Wilcoxon 
signed rank test was used for statistical comparison between 
preoperative and postoperative data.
R ESU LT S
Data from 233 patients treated at 5 centers were evalu­
ated. The distribution among the different centers, and mean 
values at baseline for age, prostate volume, maximum flow, 
post-void residual and I-PSS are shown in  table 1. Except for 
age and prostate volume, a ll other baseline characteristics 
were statistically different among the centers according to 
the Kruskal-W allis test. When baseline characteristics for 
the 3 centers that used the inclusion criteria were examined 
there was a difference between the maximum flow and post­
void residual but not I-PSS. There was no difference between 
baseline characteristics for the 2 centers that did not follow 
the inclusion criteria completely. D ata for 200, 180 and 85 
patients were available for evaluation at 3, 6 and 12 months. 
No 12-month data were availab le from center 3.
Uroflowmetry. Overall, there was an average improvement 
in  mean maximum flow rate plus or minus standard devia­
tion from 7.5 ± 3.2 m l. per second (range 2.0 to 23.0) at 
baseline to 16.4 ±5.6 (range 4.0 to 45.0) at 3 months, 16.7 ± 
5.2 (range 4.5 to 33*0) at 6 months and 16.3 ± 5.7 (range 5.0 
to 33.5) at 12 months (table 2). A ll centers achieved signifi­
cant improvement in maximum flow rate at 6 months. How­
ever, there was a difference in  the extent of improvement per 
center. Two centers treated 3 patients w ith  a maximum flow 
of more than 15 ml. per second. Exclusion of data for these 3 
patients from statistical analysis w ill not change the afore­
mentioned results significantly. M ean individual improve­
ment at 6 months was 160.4% or 10.4 ± 4.5 ml. per second 
(range —5 to 26.5). O nly 11 patients (6% ) had no improve­
ment in  maximum flow rate at 6 months.
Post-void residual O verall, there was an average decrease 
in post-void residual from 110.4 ± 84.5 ml. (range 0 to 385) at 
baseline to 31.8 ± 47.5 (range 0 to 200) at 3 months, 30.2 ± 
50.5 (range 0 to 300) at 6 months and 21.3 ± 39.0 (range 0 to 
140) at 12 months. A ll centers achieved a significant decrease 
in  post-void residual at 6 months (table 3). Mean individual 
decrease in  post-void residual at 6 months was 61.7% or 83.9 
± 74.3 ml. (range -100 to 345). O nly 13 patients (7% ) had no 
decrease in  post-void residual at 6 months.
I-PSS. Because not every patient returned the question­
naire during followup, at 3, 6 and 12 months only 191, 178 
and 79 patients, respectively, were evaluated. Overall, there 
was a decrease in  symptom score from 21.1 ± 4.8 (range 6 to 
32) at baseline to 7.1 ± 5.4 (range 0 to 23) at 3 months, 4.8 ± 
5.0 (range 0 to 35) at 6 months and 3.6 ± 3.7 (range 0 to 20) 
at 12 months. Again, a ll centers achieved a significant de­
crease in symptom score (table 4). M ean individual decrease 
in symptom score at 6 months was 75.5% or 17.1 ± 6.2 (range 
—9 to 30). Only 5 patients (3 % ) had no decrease in  symptom 
score at 6 months. Exclusion of data for the 7 patients w ith 
an I-PSS of less than 12 from statistical analysis w ill not 
change the aforementioned results significantly. There was 
no significant difference between the 6 and 12-month maxi­
mum flow, post-void residual and I- PSS  results for a ll centers 
(except center 3 because no 12-month data were available).
Sexual function questionnaire. Sexual function was as­
sessed using a questionnaire preoperatively and 6 months 
postoperatively. There were 127 sexually active patients, 
defined as those w ith a good erection for sexual intercourse 
and antegrade ejaculation. O f these patients 47% had retro­
grade ejaculation postoperatively and 12.6% complained of 
erectile function that was insufficient for sexual intercourse 
or absent.
Pressure-flow studies. Urodynam ic investigations were 
performed in 98 patients preoperatively and 6 months post­
operatively. There was im provement in  mean detrusor pres­
sure at maximum flow from 77.8 ±33.5 cm. w ater (range 28 
to 182) to 40.4 ± 20.1 (range 15 to 103). Only 6 patients
T ab le  1. B a se lin e  c h a ra c te ris tic s  fo r  cen ters  1 to 5
Center
Totals
1 2 3 4 5
No. pts. 59 53 31 30 60 233
Mean (range):
Age (yrs.) 65.0(51.2-79.2) 66.7 (55.0-79.3) 66.3 (54.3—78.9) 65.0(52.5-79.4) 68.7 (54.9-82.8) 66.3 (51.2-82.8)
Prostate vol. (ml.) 48.7 (30-101) 47.2 (27-100) 45.3 (28-96) 51.5 (17-98) 45.4 (30-96) 47.8 (17-101)
I-PSS (range) 21.3 (12-32) 20.0 (6-30) 22.6 (18-31) 17.9 (9-31) 21.8 (15-31) 21.1 (6-32)
Ml./sec. maximum flow (range) 7.9 (2.0-14.0) 8.7 (4.0-23.0) 5.7 (4,0-12.0) 9.6 (3.0-21.0) 6.1 (4.0-12.0) 7.5 (2.0-23.0)
Ml. post-void residual (range) 86.5 (0-385) 120.9 (0-350) 135.8 (0-250) 99.0 (0-350) 115.7 (0-250) 110.4 (0-385)
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Table 2. M ean m axim um  flow  a t baseline, and a t 12, 26  and 52 weeks postoperatively for centers 1 to 5
Center
Mean Ml./Sec. Maximum Flow (range)
p Value;i:
0 W k. (233 pts.) 12 Wks. (200 pts.) 26 Wks. (180 pts.) 52 Wks. (85 pts.)
1 7.9(2.0-14.0) 18.7(6.5-45.0) 17.0 (6.9-32.0) 16.8 (5.0-33.5) <0.0001
2 8.7 (4.0-23.0) 16.8 (6.0-34.0) 15.8 (5.0-33.0) 13.9 (5.0-26.0) <0.0001
3 5.7 (4.0-12.0) 15.0 (8.0-21.0) 16.7(13.0-20.0) — 0.0022
4 9.6 (3.0-21.0) 12.6 (4.0-26.0) 14.3 (4.5-30.0) 16.9(12.0-25.0) 0,031
5 6.1 (4.0—12.0) 15.8 (8.0-22.0) 17.6(10.0-24.0) 17,1(12.0-22.0) <0.0001
Totals 7.5 (2.0-23.0) 16.4 (4.0-45.0) 16.7 (4.5-33.0) 16.3 (5.0-33.5) <0.0001
* At 26 weeks.
Table 3. M ean post-vo id  residu a l at baseline, and a t 12, 26  and 52 weeks postoperatively for centers 1 to 5
Center
Mean M l. Post-Void Residual (range)
p Value*
0 W k. (233 pts.) 12 Wks. (199 pts.) 26 Wks. (180 pts.) 52 Wks. (85 pts.)
1 86.5 (0-385) 29.8 (0-200) 17.4 (0-200) 19.7 (0-140) <0.0001
2 120.9 (0-350) 34.0 (0-200) 53.0 (0-300) 17.3 (0-130) 0.0005
3 135.8 (0-250) 38.7 (0-150) 41.7 (0-100) — 0.0150
4 99.0 (0-350) 13.9 (0-150) 44.0 (0-150) 15.0 (0-60) 0.0180
5 115.7 (0-250) 34.2 (0-170) 22.5 (0-150) 26.8 (0-135) <0.0001
Totals 110.4 (0-385) 31.8 (0-200) 30.2 (0-300) 21.3 (0-140) <0.0001
* At 26 weeks.




0 Wk. (233 pts.) 12 Wks. (191 pts.) 26 Wks. (178 pts.) 52 Wks. (79 pts.)
1 21.3(12-32) 7.9 (0-23) 6.1(0-35) 4.8 (0-20) <0.0001
2 20.0 (6-30) 6.7(0-23) 5.7(0-26) 3.0 (0-6) <0.0001
3 22.6 (18-31) 4.8 (0-18) 2.9 (0-7) — 0.0007
4 17.9 (9-31) 7.4 (1-19) 4.7 (0-10) 3.7 (2-7) 0.0117
5 21.8(15-31) 7.2 (1-22) 3.6 (0-18) 3.1 (0-12) <0.0001
Totals 21,1 (6-32) 7.1 (0-23) 4.8 (0-35) 3.6 (0-20) <0.0001
* A t 26 weeks.
(6.1%) had no decrease in  detrusor pressure at maximum 
flow. There was a sim ilar improvement in  the linear passive 
urethral resistance relation when using the Schäfer nomo­
gram, as well as in  urethral resistance relation (table 5). 
Only 3 patients (3.1%) had no decrease in  linear passive 
urethral resistance relation and 6 (6.1%) had no decrease in 
urethral resistance relation. The Abrams-Griffith nomogram 
showed a shift from the obstructed to the equivocal and 
unobstructed areas (see figure).
Morbidity. No complications were encountered during la ­
ser prostatectomy. Four patients (1.7%) had urinary reten­
tion after removal of the suprapubic catheter and 3 (1.3%) 
had clot retention. One of the 3 patients required cystoure- 
throscopy w ith general anesthesia. No bleeding was noted 
from the prostatic urethra but bleeding occurred at the entry 
of the suprapubic catheter, which was controlled w ith elec­
trocoagulation. No patient w ith  clot retention required blood
transfusion. During the first 4 to 6 weeks approximately 50% of 
the patients complained of irritative voiding symptoms, which 
consisted mainly of stranguria, urgency and frequency. Urinary 
tract infection was diagnosed in 21.1% of the patients.
Reoperation. Because of minimal or no improvement after 
laser treatment transurethral resection of the prostate was 
performed in 11 patients (4.7%), a second laser treatment in 
4(1.7%) and bladder neck incision in 3 (1.3%). Visual internal 
urethrotomy was necessary in 1 patient (0.4%) because of 
urethral stricture. Patients who required transurethral re­
section of the prostate or a second laser treatment had resid­
ual prostatic tissue at cystourethroscopy.
D ISC U SSIO N
Since the first publications of side firing laser fibers for 
treatment of symptomatic B P H  by Costello9 and McCullough10
Table 5. U rodynam ic param eters before and 26 weeks after laser prostatectom y
Mean (range)
p Value
0 Wk. 26 Wks.
Overall:
Urethral resistance relation (cm. water)
Linear passive urethral resistance relation 
Detrusor pressure at maximum flow (cm. water) 
Center 1:
Urethral resistance relation (cm. water)
Linear passive urethral resistance relation 
Detrusor pressure at maximum flow (cm. water) 
Center 5:
Urethral resistance relation (cm. water)
Linear passive urethral resistance relation 
Detrusor pressure at maximum flow (cm. water)
52.2 (13-133) 20.7 (6-70) <0.0001
3.7 (0-6) 1.2 (0-5) <0.0001
77.8 (28-182) 40.4 (15-103) <0.0001
51.9 (23-133) 17.7 (6-41) <0.0001
3.6 (1-6) 0.9 (0-4) <0.0001
76.5 (34-150) 35.7 (15-78) <0.0001
52.7(13-101) 25.4 (8-70) <0.0001
3.8 (0-6) 1.7 (0-5) <0.0001
80.4 (28-182) 47.7 (15-103) <0.0001
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Qmax (ml/s)
Changes in detrusor pressure (Pdet) at maximum flow (Qmax) before and 6 months after laser prostatectomy using Abrams-Griffiths 
nomogram for centers 1 and 5. A, baseline. • ,  26 weeks.
et al, reports on laser prostatectomy have increased.11-1,1 A l­
though all of these studies revealed significant subjective and 
objective results, there seemed to be a difference in extent of 
improvement. Sim ilar differences among centers were docu­
mented in our study. However, because of different baseline 
characteristics the results of the individual centers are difficult 
to compare. A ll participating centers achieved significant im­
provement in I-PSS and maximum flow but there was a differ­
ence in extent of improvement among the centers. A  reason for 
this observation may be an alteration in the way laser energy 
was applied despite the fact that most patients were treated 
according to the same protocol. Kabalin and G ill described a 
significant decrease in amount of coagulation necrosis when the 
laser application was interrupted for approximately 30 sec­
onds.21 In  addition, the distance of the fiber tip to the prostatic 
surface is difficult to standardize and may vary, resulting in  
different power densities and amounts of coagulation necrosis 
achieved. Another explanation for differences in results may be 
variation in interpretation of the uroflowmetry curves. How­
ever, in our study all flow curves were reviewed by 2 indepen­
dent investigators.
To compare the laser procedure to the gold standard trans­
urethral resection of the prostate, a few randomized studies 
were performed that showed no statistically significant dif­
ferences in  objective and subjective results between the 2 
procedures.22-25 W ith  regard to morbidity, there appeared to 
be a shift from perioperative and immediate postoperative 
morbidity, such as the transurethral resection syndrome, 
bleeding and the need for blood transfusion, which in the 
literature is greater for transurethral resection of the pros­
tate, to postoperative morbidity, such as transient voiding 
complaints, prolonged catheterization and urinary tract in ­
fections, which were greater for laser prostatectomy. We 
must note that complications after transurethral resection of 
the prostate probably are more severe than those after laser 
prostatectomy. Approximately 50% of our patients had irr i­
tative voiding symptoms lasting 4 to 6 weeks after laser 
prostatectomy and 21.1% had urinary tract infection. Irrita ­
tive voiding complaints can be explained partly by the long
catheterization period (17 days in  our study). On the other 
hand, several patients w ith  a short catheterization period 
had irrita tive  voiding com plaints for approximately 4 weeks. 
A  previous study showed the same results but did not dem­
onstrate a relationship between irrita tive  complaints and 
incidence of urinary tract infection.26 However, that study 
showed a relationship between prolonged catheterization 
and incidence of urinary tract infection, which m ight also 
explain the significant incidence of u rinary tract infection in 
our study. Use of a suprapubic catheter in  our study, which 
was removed only when post-void residual was less than 50 
ml., could be the reason for th is prolonged catheterization. 
Also, the reoperation rate after 1 year was great in  our study, 
w ith transurethral resection of the prostate in  4.7% of the 
cases, second laser treatm ent in  1.7% and bladder neck inci­
sion in  1.3%. V isual in ternal urethrotom y was necessary in  1 
patient (0.4%). These findings are in  contrast to other studies 
by Kabalin ,11 and N orris12 and Leach13 et al, who reported 
only a few patients undergoing a second laser treatm ent, and 
only Norris et a l reported on 3 patients in  whom a transure­
thral resection of the prostate after in itia l laser therapy was 
performed. This fact m ay be explained by a shorter followup 
in these studies or a difference in  selection criteria. I t  gener­
ally is known that European surgeons usually treat patients 
with more advanced disease, resulting in  treatm ent of larger 
prostates, and these patients m ay be at increased risk  for 
reoperation following laser prostatectomy.
However, when analyzing the baseline characteristics of 
patients in whom laser prostatectom y failed and who subse­
quently required a  second laser treatm ent or transurethral 
resection of the prostate, we found no significant difference 
compared to the other patients. Factors, such as differences in 
prostate tissue texture27 or those that influence the power 
density during laser treatm ent, probably w ill explain the 
differences in  clinical outcome.
Previous reports concerning results of laser prostatectomy 
described only a slight percentage of patients w ith retrograde 
ejaculation. In  contrast, retrograde ejaculation occurred in 
47% of our patients who had norm al ejaculation before laser
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treatment, probably because in  our study we were more 
accustomed to working w ith  lasers and, therefore, applied 
more energy to the prostate, bladder neck or middle lobe than 
when we first began performing laser prostatectomy. Fu r­
thermore, 12.6% of our patients who reported no erectile 
dysfunction before laser prostatectomy had absent or dimin­
ished erectile function after treatment. Sexual question­
naires were used to obtain this information, and no objective 
evaluation was performed. Therefore, it is most likely that 
some of these patients already had some degree of erectile 
dysfunction before laser treatment.
Pressure-flow study analysis is the only method to demon­
strate objectively relief of bladder outlet obstruction. Since 
Abrams and G riffith  first reported urodynamic changes after 
surgical intervention for B P H ,19 there have been few studies 
on this subject. To date only a lim ited number of studies have 
been presented using pressure-flow parameters for evalua­
tion of treatm ent outcome after laser therapy. Bosch et al 
showed a decrease in  detrusor pressure at maximum flow 
and urethral resistance relation after laser prostatectomy 
with the T U L IP  device.18 de W ild t17 and te Slaa16 et al also 
reported significant improvement in urodynamic parameters 
after laser prostatectomy w ith the T U L IP  device and 2 dif­
ferent side firing lasers (Urolase and U ltraline laser fibers). 
A  randomized study by Kabalin  et al showed equal improve­
ment in  opening pressure and maximal detrusor pressure in 
both treatm ent arms.15 In  our study pressure-flow analysis 
was performed at centers 1 and 5, and showed overall im­
provement in  urodynamic parameters sim ilar to that in  the 
literature.15"18 Because pressure-flow analysis results were 
not inclusion criteria, some patients had no urodynamic ob­
struction preoperatively. There was no statistically signifi­
cant difference between the 2 centers. Therefore, we believe 
that laser prostatectomy is the only documented alternative 
treatment modality today that can achieve urodynamic re­
sults comparable to those of transurethral resection of the 
prostate in a large series of patients.
C O N C LU SIO N S
Laser prostatectomy results in  significant subjective and ob­
jective improvement, which is operator independent. However, 
minor differences may be noted, possibly due to variation of 
technique or different selection criteria. Despite the observation 
that perioperative morbidity seems less severe compared to 
transurethral resection of the prostate, there is a shift toward 
greater postoperative morbidity. Pressure-flow analysis shows 
that laser prostatectomy can relieve bladder outlet obstruction. 
Future studies should be focused on optimizing dosimetry and 
improving laser technologies, resulting in minimal morbidity, 
and probably selecting a subgroup of patients who w ill benefit 
the most from this treatment modality.
The urodynamic analysis program was developed at the 
U IC /BM E Research Centre, Departm ent of Urology, N ijm e­
gen, The Netherlands.
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EDITORIAL COMMENT
The Dutch have undoubtedly established themselves as some of 
the premier laser prostatectomists in the world. The authors and 
others of their countrymen have provided us with multiple important 
clinical reports and scientific studies of free beam neodymium:YAG 
laser prostatectomy, and particularly have enhanced our under­
standing of the instrumentation and physical mechanisms underly­
ing this operation (reference 17 in article).1- 4 The authors summa­
rize a large prospective clinical experience with neodymium :YAG 
laser prostatectomy cumulated from 5 medical centers in The Neth­
erlands. Statistically and clinically significant improvement is doc­
umented for all measures of voiding outcome, including complex 
urodynamic evaluation with pressure-flow studies—the latter inva­
sive data collection is obtained too seldom for any of our BPH ther­
apies. These outcomes from laser prostatectomy are uniformly com­
parable to those expected from electrocautery resection. As the 
authors accurately contend, laser prostatectomy is the only treat­
ment modality for BPH today (except, of course, open prostatectomy) 
that has achieved urodynamic results in large series of patients 
comparable to those of electrocautery resection. The retrograde ejac­
ulation rate of 47% in this series is the highest yet reported for laser 
prostatectomy, and speaks perhaps more than any other outcome to 
the fact that the authors are performing an aggressive, truly debulk- 
ing prostatectomy with the neodymium:YAG laser.
The authors note irritative voiding complaints in up to 50% of 
patients. I am only surprised that this proportion is not greater, 
since all of their patients were treated with a suprapubic catheter for 
an average of 17 days postoperatively. Suprapubic catheters have 
been similarly problematic in my experience after laser prostatec­
tomy. For reasons that may not be completely understood, they tend 
to cause much more bladder irritation than a uretliral Foley cathe­
ter, and perhaps because of this irritation they tend to stay in much 
longer postoperatively before an adequate voiding trial is completed.
With longer catheterization times come higher rates of infection, 
documented in more than 21% of patients in this series, and even 
more irritative symptoms due to the infections. It also is notable that 
the only significant complication in this series was bleeding from a 
suprapubic catheter insertion site and not from the laser coagulated 
prostate, which caused clot retention and required reoperation for 
fulguration. The only patients in whom I find a suprapubic catheter 
to be a reasonable management option following laser prostatectomy 
are those already in chronic retention with a long-term catheter 
preoperatively, who have motor and sensory neurogenic bladder 
dysfunction. This small subset of patients does not experience an 
acute exacerbation of irritative symptoms with the suprapubic cath­
eter postoperatively, and in these cases the multiple voiding trials 
that are often necessitated by the detrusor dysfunction are facili­
tated by the suprapubic catheter.
John N . K abalin  
D epartm en t o f Urology 
S tan ford  U n iversity  School o f M edicine 
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